Slide 1: Company Review
Company Review Dr Nina Webster CEO & Managing Director @w Dimerix
Slide 2: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different fro
Slide 3: FY2020 milestones and beyond
For personal use only FY 2020 FSGS Phase 2a study 1st DMX-200 patents Diabetic Kidney Complete GMP DMX-700 added to 2nd Innovation Connections fully recruited announced in Europe Disease Phase 2 study commercial batch pipeline Grant awarded Jul19 Jul19 fully recruited manufacture Oct19 Oct19 Sep19 O
Slide 4: Product candidates in the pipeline
For personal use only 4 product candidates in the pipeline, with 3 clinical opportunities Pivotal Study Preclinical Phase 1 Phase 2 Market Compound Disease Target Acute Respiratory Distress Syndrome DMX-200 (ARDS) in COVID-19 patients Focal Segmental Glomerulosclerosis DMX-200 (FSGS) DMX-200 Diabeti
Slide 5: DMX-200 in Renal Overview
DMX-200 in Renal Overview
Slide 6: DMX-200 clinical studies
For personal use only Phase 1 study (DMX-200-101) Phase 2a study (DMX-200-201) Phase 2a study (DMX-200-202) Phase 2 study (DMX-200-203) • Healthy volunteers • Chronic Kidney Disease • Focal Segmental • Diabetic kidney disease ➢ Pharmacokinetic, ➢ Safety and tolerability Glomerulosclerosis ➢ Efficacy
Slide 7: Kidney disease intervention schematic
Kidney disease intervention schematic = Kidney disease is progressive”: Healthy kidney * loss of kidney function over a period of time Nn . yi >. develop permanent kidney failure eventually, kidney function declines and patients Early diagnosis at 30 mg/mmol 57 mg/mmol: . also early diagnosis Ae DMX
Slide 8: Renal market opportunity
For personal use only Ɨ ǂ • ǂ • ^ Alicic R, Rooney M, Tuttle K (2017) Diabetic Kidney Disease Challenges, Progress, and Possibilities, Clinical Journal of American Society of Nephrology [https://cjasn.asnjournals.org/content/12/12/2032] [Accessed 02Mar20] * Market Research Future (2020); Diabetic Ne
Slide 9: DMX-200 in Acute Respiratory Distress Syndrome Overview
DMX-200 in Acute Respiratory Distress Syndrome Overview
Slide 10: For personal use only
• • • • For personal use only • • • • • •
Slide 11: Acute Respiratory Distress Syndrome (ARDS) REMAP-CAP
Acute Respiratory Distress Syndrome (ARDS) COVID-19 patients — awarded $1 millio P-CAP REMAP-CAP: global WHO. endorsed clinical study; >200 clinical sites in 16 countries* REMAP-CAP has been designated by the WHO asa Pandemic Special Study* translation of clinical trial results occur directly with p
Slide 12: DMX-700 in Chronic Obstructive Pulmonary Disease Overview
DMX-700 in Chronic Obstructive Pulmonary Disease Overview
Slide 13: COPD market opportunity
Asia Pacific expected to be For personal use only fastest growing Global Initiatives COPD market at CAGR ~8.7% Global COPD • World Health Organization (WHO) treatment market No candidates in • COPD Foundation US$14 billion (2017) late stage & projected to • American Thoracic Society development incr
Slide 14: DMX-700 overview
DMxX-700 overview DMX-700: oral administration candidate: * Two molecules working together, each with an established safety profile ¢ Dimerix has completed initial studies on receptors involved in COPD * Certain lung cells express multiple receptors, thus blocking only one receptor does not block si
Slide 15: Financial Outcomes & Value Driving Events
Financial Outcomes & Value Driving Events
Slide 16: Financial outcomes
For personal use only R&D investment costs increased Cash Reserves at June 2020 $7.8 million FY2020 net operating cash expenditure $4.7m Corporate/ Administration costs decreased
Slide 17: Top shareholders and share price performance
For personal use only Top 10 shareholders Share price performance *June 2020 quarter
Slide 18: Value driving events
For personal use only FSGS $1million grant awarded Diabetic Kidney Ongoing partnering Prepare for phase 2 data for ARDS in COVID-19 Disease Phase 2 data activities and discussions commercial scale Jul20 Sep20 manufacturing DMX-700 pre-IND DMX-200 Initiate pivotal Ph3 study DMX-200 FSGS DMX-700 in vi
Slide 19: End of Presentation
DIMERIX End of Presentation 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. bd@dimerix.com